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INTRODUCTIONThe changing face of care for venous disease
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MVaricose veins and associated chronic venous diseases
afflict millions of people worldwide. Progress in minimally
invasive, endovascular techniques, and technology, includ-
ing laser and radiofrequency ablation, has rapidly trans-
formed the way we care for patients with venous disease
today. Patient acceptance of mostly office-based, outpa-
tient treatments of varicose veins, and more advanced
chronic venous diseases, has been unprecedented, and clin-
ical outcomes after minimally invasive venous ablations
have been unexpectedly good. Interest in venous disease, a
stepchild of medicine just a few decades ago, has grown
immensely among patients, physicians, and device manu-
facturers, as well as third party payers. Testimony to this is
the ever-increasing number of interventions performed in
the United States.
The growing public awareness and interest, the increas-
ing number of venous procedures performed by vascular
surgeons, and also by physicians of other specialties, cou-
pled with unparalleled enthusiasm of the medical industry
to invest in technology and to contribute to generate
scientifically valid data on safety and efficacy of the proce-
dures fueled remarkable academic progress in the venous
field. Evidence-based medicine, hardly typical of venous
disease just before the turn of the century, has changed the
way we decide on appropriate indications, safe and cost-
effective techniques and on outcome assessment after ve-
nous interventions.
The two major stakeholders in the field of venous disease
include the Society for Vascular Surgery (SVS), the largest
North American not-for-profit organization dedicated to the
prevention, investigation, and management of vascular dis-
eases and its close ally, the American Venous Forum (AVF), a
multidisciplinary society founded by members of the SVS;
both organizations are fully devoted to the education and
research of venous disease. During the past 2 decades, the
objectives of both organizations have been to develop inter-
nationally accepted and standardized venous nomenclature
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ent tools, position statements, and practice guidelines. The
wo organizations, together with the Foundation of the SVS,
he American Vascular Association, worked side by side to
ncrease public awareness by campaigns and by screening for
enous disease. The AVF recently introduced a national Ve-
ous Registry and launched a major initiative in the United
tates to decrease the prevalence of venous ulcers.
The objective of this Supplement of the Journal of
ascular Surgery is to present current scientific evidence on
utcome after treatment of varicose veins and associated
hronic venous diseases and to provide guidelines for their
anagement. Members of the Venous Guideline Committee
f the SVS and AVF formulate recommendations on “best
ractice” for evaluation of chronic venous disease and present
p-to-date evidence on safety, efficacy, cost-effectiveness, and
urability of medical, surgical, and endovascular procedures.
he committee carefully weighed the benefits and harms of
ach old and new venous intervention. Based on the available
vidence, the Venous Guideline Committee recommended
linical practice guidelines for the management of varicose
eins and associated more advanced chronic venous diseases.
n a separate article of the Supplement, a systematic review
valuated results of 38 comparative studies, including 29
andomized controlled trials, to collect and grade evidence on
urgery, laser ablation, radiofrequency treatment, and liquid
r foam sclerotherapy of varicose veins.
Indisputably, clinical practice guidelines need to be
pdated as the technology is changing and robust scientific
ata on efficacy of any new procedure become available.
he rapidly transforming face of the care for patients with
enous disease easily predicts that further changes in the
anagement of venous disease are almost inevitable. Al-
hough transformation of our venous practice in the last
ecade has been unusually fast, medicine has been used to
evolutionary progress. As Dr Charles H. Mayo said it
lready in 1931, “. . . the only thing that is permanent is
hange.”
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